A groundbreaking Alzheimer's treatment, Leqembi is a monoclonal antibody targeting amyloid-beta plaques in the brain. Administered via intravenous infusion, it slows cognitive decline in early-stage patients. By clearing toxic protein buildup, this therapy benefits those with mild cognitive impairment or mild dementia, offering a chance to preserve function and quality of life longer.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends